Scailyte has established a biomarker discovery platform that utilizes artificial intelligence to extract insights from single-cell molecular data. This gives us the ability to rapidly identify disease-associated cells and use this knowledge to develop ultra-sensitive molecular diagnostics. We first applied this approach in skin T-cell lymphoma and discovered a biomarker that detects the disease with an unprecedented accuracy of 95%. We are now scaling up our biomarker discovery effort into multiple indications in oncology and women's health.